This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.

Scroll down

Wegovy<sup>®</sup>

Wegovy® (semaglutide injection 2.4 mg) is the first once-weekly GLP-1 RA* indicated for weight management, helping your patients obtain a 16.7% (17.6 kg) mean weight loss sustained over 2 years.**1-2
 

*GLP-1 RA, glucagon-like peptide-1 receptor agonist.
**At 104 weeks, mean weight loss was 16.7% vs. 0.6% with placebo in the STEP 5 trial2

Wegovy<sup>®</sup>

Wegovy® (semaglutide injection 2.4 mg) is the first once-weekly GLP-1 RA* indicated for weight management, helping your patients obtain a 16.7% (17.6 kg) mean weight loss sustained over 2 years.**1-2
 

*GLP-1 RA, glucagon-like peptide-1 receptor agonist.
**At 104 weeks, mean weight loss was 16.7% vs. 0.6% with placebo in the STEP 5 trial2